Kratom Research Institute

Policy · 2026-07-06

Federal Register: DEA Proposes Schedule I for Mitragynine Pseudoindoxyl, MGM-15, and MGM-16

Source: Federal Register

Why it matters

Three synthetic opioid compounds derived from kratom chemistry — products of research labs that migrated to gas station shelves — are now formally proposed for Schedule I, which would make their manufacture, sale, or possession federally illegal.

The big picture

Mitragynine pseudoindoxyl first appeared in commercial products in 2024. MGM-15 hit retail in September 2025. Both are now sold as flavored chewable tablets in smoke shops and online, often marketed under deceptive "botanical" branding. The DEA found 25 fatal overdose events involving mitragynine pseudoindoxyl between February 2025 and February 2026 in its toxicology program data.

Key findings

What they say

HHS Secretary Robert F. Kennedy, Jr. stated: "I commend the DEA for taking decisive action to address these addictive and harmful substances. 7-OH, MP, MGM-15, and MGM-16 are dangerous opioids that fuel addiction and put American lives at risk. HHS reviewed the science and recommended this action."

Bottom line

Three kratom-derived synthetic opioids — some up to 240 times more potent than morphine — are headed for Schedule I federal prohibition as early as August 5, 2026.